Chargement en cours...
Mucin 1-specific active cancer immunotherapy with tecemotide (L-BLP25) in patients with multiple myeloma: An exploratory study
Patients (n = 34) with previously untreated, slowly progressive asymptomatic stage I/II multiple myeloma or with stage II/III multiple myeloma in stable response/plateau phase following conventional anti-tumor therapy were immunized repeatedly with the antigen-specific cancer immunotherapeutic agent...
Enregistré dans:
| Publié dans: | Hum Vaccin Immunother |
|---|---|
| Auteurs principaux: | , , , , , , , |
| Format: | Artigo |
| Langue: | Inglês |
| Publié: |
Taylor & Francis
2014
|
| Sujets: | |
| Accès en ligne: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4514088/ https://ncbi.nlm.nih.gov/pubmed/25483677 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.4161/hv.29918 |
| Tags: |
Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!
|